Exome Asset Management LLC Buys Shares of 88,148 Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Exome Asset Management LLC purchased a new position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 88,148 shares of the company’s stock, valued at approximately $797,000. Exome Asset Management LLC owned approximately 0.27% of Lexeo Therapeutics at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Janus Henderson Group PLC grew its holdings in Lexeo Therapeutics by 18.9% during the 3rd quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock worth $33,997,000 after acquiring an additional 599,203 shares in the last quarter. Frazier Life Sciences Management L.P. bought a new position in shares of Lexeo Therapeutics during the third quarter valued at approximately $11,307,000. Vestal Point Capital LP increased its holdings in Lexeo Therapeutics by 1.2% during the third quarter. Vestal Point Capital LP now owns 850,000 shares of the company’s stock valued at $7,684,000 after buying an additional 10,000 shares during the period. Verition Fund Management LLC raised its stake in Lexeo Therapeutics by 84.5% in the third quarter. Verition Fund Management LLC now owns 777,320 shares of the company’s stock worth $7,027,000 after buying an additional 355,928 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Lexeo Therapeutics by 86.5% during the third quarter. Geode Capital Management LLC now owns 553,247 shares of the company’s stock worth $5,003,000 after buying an additional 256,635 shares during the period. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on LXEO shares. Chardan Capital upped their price objective on Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright upped their price target on Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, November 14th. Finally, Leerink Partners lowered their price objective on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Wednesday, November 13th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $23.80.

Insider Activity

In other news, CEO Richard Nolan Townsend sold 5,000 shares of the company’s stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $8.10, for a total value of $40,500.00. Following the sale, the chief executive officer now directly owns 120,695 shares of the company’s stock, valued at $977,629.50. This represents a 3.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have sold 10,000 shares of company stock valued at $80,550. Company insiders own 4.50% of the company’s stock.

Lexeo Therapeutics Price Performance

NASDAQ LXEO opened at $6.88 on Friday. The stock’s fifty day moving average price is $8.13 and its 200 day moving average price is $11.36. Lexeo Therapeutics, Inc. has a 1 year low of $5.77 and a 1 year high of $22.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. The company has a market cap of $227.49 million and a price-to-earnings ratio of -2.16.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.